HK1256651A1 - 重組hcmv和rhcmv載體以及它們的用途 - Google Patents

重組hcmv和rhcmv載體以及它們的用途

Info

Publication number
HK1256651A1
HK1256651A1 HK18115806.2A HK18115806A HK1256651A1 HK 1256651 A1 HK1256651 A1 HK 1256651A1 HK 18115806 A HK18115806 A HK 18115806A HK 1256651 A1 HK1256651 A1 HK 1256651A1
Authority
HK
Hong Kong
Prior art keywords
recombinant hcmv
rhcmv vectors
rhcmv
vectors
hcmv
Prior art date
Application number
HK18115806.2A
Other languages
English (en)
Inventor
Louis Picker
Jay A Nelson
Klaus Frueh
Michael A Jarvis
Scott G Hansen
Original Assignee
Univ Oregon Health & Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/029930 external-priority patent/WO2011119920A2/en
Application filed by Univ Oregon Health & Science filed Critical Univ Oregon Health & Science
Publication of HK1256651A1 publication Critical patent/HK1256651A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/04—Varicella-zoster virus
    • C07K14/045—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/161—HIV-1 ; HIV-2 gag-pol, e.g. p55, p24/25, p17/18, p7, p6, p66/68, p51/52, p31/34, p32, p40
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16161—Methods of inactivation or attenuation
    • C12N2710/16162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18115806.2A 2010-05-14 2018-12-10 重組hcmv和rhcmv載體以及它們的用途 HK1256651A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33497610P 2010-05-14 2010-05-14
US37691110P 2010-08-25 2010-08-25
PCT/US2011/029930 WO2011119920A2 (en) 2010-03-25 2011-03-25 Cmv glycoproteins and recombinant vectors

Publications (1)

Publication Number Publication Date
HK1256651A1 true HK1256651A1 (zh) 2019-09-27

Family

ID=44915020

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18115806.2A HK1256651A1 (zh) 2010-05-14 2018-12-10 重組hcmv和rhcmv載體以及它們的用途
HK18116180.6A HK1257045A1 (zh) 2010-05-14 2018-12-18 編碼從副粘病毒科病毒中分離的異源抗原的重組hcmv和rhcmv載體及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18116180.6A HK1257045A1 (zh) 2010-05-14 2018-12-18 編碼從副粘病毒科病毒中分離的異源抗原的重組hcmv和rhcmv載體及其用途

Country Status (18)

Country Link
US (3) US9249427B2 (zh)
EP (5) EP3739054A1 (zh)
AU (5) AU2011252792C1 (zh)
CA (2) CA3040225A1 (zh)
CY (4) CY1119944T1 (zh)
DK (3) DK2569436T3 (zh)
ES (4) ES2788198T3 (zh)
HK (2) HK1256651A1 (zh)
HR (4) HRP20180267T1 (zh)
HU (4) HUE036122T2 (zh)
LT (4) LT2569436T (zh)
NO (2) NO2569436T3 (zh)
PL (4) PL3333265T3 (zh)
PT (3) PT3351636T (zh)
RS (2) RS57274B1 (zh)
SI (4) SI3333265T1 (zh)
TR (1) TR201802741T4 (zh)
WO (2) WO2011143653A2 (zh)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2529227B1 (en) * 2010-01-27 2015-10-07 Oregon Health & Science University Cytomegalovirus-based immunogenic preparations
WO2011119920A2 (en) * 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
PT3351636T (pt) 2010-05-14 2020-09-24 Univ Oregon Health & Science Vectores de hcmv e rhcmv recombinantes codificadores de um antigénio heterólogo isolado a partir de um vírus paramyxoviridae e seus usos
AU2012243463B2 (en) * 2011-04-15 2017-04-13 Cecilia Naucler Genetic variant of cytomegalovirus (CMV)
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
US20150307850A1 (en) * 2012-12-04 2015-10-29 Merck Sharp & Dohme Corp. Conditional replicating viral vectors
EP3919505B1 (en) 2013-01-16 2023-08-30 Emory University Uses of cas9-nucleic acid complexes
GB201301119D0 (en) * 2013-01-22 2013-03-06 Vaxxit Srl Viral vaccines
ES2696703T3 (es) * 2013-03-05 2019-01-17 Univ Oregon Health & Science Vectores de citomegalovirus que permiten el control del direccionamiento de los linfocitos T
US20140335115A1 (en) * 2013-05-07 2014-11-13 Oregon Health & Science University Suppressors of mature t cells
WO2015061851A1 (en) * 2013-10-29 2015-05-07 The University Of Sydney Cmv immuno-stimulatory composition
DK3113795T3 (da) * 2014-03-01 2019-10-21 Univ Texas Rekombinante virale isfahan-vektorer
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
US10428118B2 (en) * 2014-07-16 2019-10-01 Oregon Health & Science University Human cytomegalovirus comprising exogenous antigens
MA40783A (fr) * 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
GB201501523D0 (en) * 2015-01-30 2015-03-18 Univ Plymouth Differential immune response modulation
AU2016219317A1 (en) * 2015-02-10 2017-08-31 Oregon Health & Science University Methods and compositions useful in generating non canonical CD8+ T cell responses
US20160346362A1 (en) * 2015-05-29 2016-12-01 Agenovir Corporation Methods and compositions for treating cytomegalovirus infections
US10117911B2 (en) 2015-05-29 2018-11-06 Agenovir Corporation Compositions and methods to treat herpes simplex virus infections
GB201514034D0 (en) * 2015-08-08 2015-09-23 Univ Plymouth Improvements in or relating to DNA recombination
CA3005136A1 (en) 2015-11-20 2017-05-26 Oregon Health & Science University Cmv vectors comprising microrna recognition elements
US11351237B2 (en) 2015-12-22 2022-06-07 Thomas Jefferson University CMV-based intra-tumoral cancer therapies
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
CA3028827A1 (en) * 2016-06-22 2017-12-28 Aeras Recombinant cytomegalovirus vectors as vaccines for tuberculosis
EP3475446A1 (en) * 2016-06-27 2019-05-01 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
MA46588A (fr) * 2016-10-18 2021-04-14 Univ Oregon Health & Science Vecteurs de cytomégalovirus déclenchant des lymphocytes t limités par des molécules e de complexe majeur d'histocompatibilité
US11638749B2 (en) 2017-10-17 2023-05-02 International Aids Vaccine Initiative, Inc. Tuberculosis antigen cassettes
EP3762025A4 (en) * 2018-03-09 2021-12-01 The Regents of the University of California VECTORS OF CMV AND ASSOCIATED USES
WO2019209632A1 (en) 2018-04-24 2019-10-31 Merck Sharp & Dohme Corp. Scalable chromatography process for purification of human cytomegalovirus
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
US20220090005A1 (en) 2019-01-03 2022-03-24 Merck Sharp & Dohme Corp. Supplemented Serum-Containing Culture Medium for Enhanced Arpe-19 Growth and Human Cytomegalovirus Vaccine Production
US11077185B2 (en) 2019-03-21 2021-08-03 21C Bio Vaccine to pathogenic immune activation cells during infections
JP2022526628A (ja) 2019-03-21 2022-05-25 ２１シー バイオ 感染時の病原性免疫活性化細胞に対するワクチン
US10632186B1 (en) 2019-03-21 2020-04-28 21C Bio Vaccine to pathogenic immune activation cells during infections
EP3980071A4 (en) * 2019-06-07 2023-10-11 Oregon Health & Science University TUMOR-ASSOCIATED ANTIGEN-SPECIFIC T-CELL REACTIONS
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
WO2023034801A1 (en) 2021-08-31 2023-03-09 Vir Biotechnology, Inc. Recombinant hcmv vectors and uses thereof
IL310667A (en) 2021-08-31 2024-04-01 Vir Biotechnology Inc Tuberculosis vaccines
JP2024532231A (ja) * 2021-08-31 2024-09-05 ヴィア・バイオテクノロジー・インコーポレイテッド Ｃｍｖベクターを産生するための方法
WO2023059112A1 (ko) * 2021-10-06 2023-04-13 주식회사 지앤피바이오사이언스 최적의 재조합 발현 구축물의 개발
AU2023204775A1 (en) * 2022-01-07 2024-07-25 Mayo Foundation For Medical Education And Research Cytomegalovirus vectors and methods of use
WO2024121424A1 (en) 2022-12-09 2024-06-13 Daniel Zagury Composite aids vaccine generating anti-hiv specific neutralizing antibodies and/or anti-hiv cytotoxic t cells

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267965B1 (en) * 1981-12-24 2001-07-31 Virogenetics Corporation Recombinant poxvirus—cytomegalovirus compositions and uses
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5273876A (en) 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
ATE118822T1 (de) 1987-06-26 1995-03-15 Syntro Corp Rekombinanter, fremde gene enthaltender menschlicher cytomegalovirus und seine verwendung.
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
EP1092775A1 (en) 1991-07-05 2001-04-18 American Cyanamid Company Methods for identifiying non-essential genes of the human cytomegalovirus genome and for screening for inhibitors of human cytomegalovirus
AU7192394A (en) * 1993-07-19 1995-02-20 Cantab Pharmaceuticals Research Limited Production method for preparation of disabled viruses
US5833993A (en) 1994-04-29 1998-11-10 Pharmacia & Upjohn Company Feline immunodeficiency virus vaccine
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5846806A (en) 1994-07-29 1998-12-08 American Cyanamid Company Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
ES2264136T3 (es) * 1995-02-21 2006-12-16 Cantab Pharmaceuticals Research Limited Preparaciones virales, vectores, inmunogenos y sus vacunas.
WO1996031241A1 (en) 1995-04-04 1996-10-10 Cell Genesys, Inc. Transplantation of genetically modified cells having low levels of class i mhc proteins on the cell surface
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
PT966301E (pt) 1996-07-31 2005-06-30 Ortho Mcneil Pharm Inc Identificacao de genes do citomegalovirus humano envolvidos na regulacao negativa da expressao da cadeia pesada do mhc classe i
US6214806B1 (en) 1997-02-28 2001-04-10 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
US20030138454A1 (en) * 1997-06-09 2003-07-24 Oxxon Pharmaccines, Ltd. Vaccination method
DE19733364A1 (de) * 1997-08-01 1999-02-04 Koszinowski Ulrich H Prof Verfahren zur Klonierung eines großen Virusgenoms
AU3910097A (en) * 1997-08-05 1999-03-01 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Live recombinant vaccine comprising inefficiently or non-replicating vir us
CA2323929C (en) 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US20020102536A1 (en) * 1999-11-19 2002-08-01 Xenova Research Limited Preparation of human or animal herpesviruses
US7204990B1 (en) * 2000-11-28 2007-04-17 Medimmune Vaccines, Inc. Attenuation of cytomegalovirus virulence
WO2002062296A2 (en) 2001-02-02 2002-08-15 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
CA2438322A1 (en) 2001-02-21 2002-08-29 Gabriele Hahn Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates
GB0122232D0 (en) * 2001-09-14 2001-11-07 Medical Res Council Gene expression
EP1427826B1 (en) * 2001-09-20 2011-04-20 Glaxo Group Limited HIV- RT-nef-Gag codon optimised DNA vaccines
NZ532383A (en) * 2001-11-21 2007-03-30 Univ Pennsylvania Pan-7 simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
US20030118568A1 (en) 2001-12-18 2003-06-26 Board Of Trustees Of The University Of Arkansas Viral stealth technology to prevent T cell-mediated rejection of xenografts
EP1497412A4 (en) * 2002-04-30 2006-11-22 Avior Therapeutics Inc ADENOVIRUS VECTORS FOR IMMUNOTHERAPY
AU2003232745B2 (en) * 2002-05-08 2009-01-29 Intervet International B.V. Brachyspira hyodysenteriae vaccine
DE10232322A1 (de) 2002-07-16 2004-07-29 Hahn, Gabriele, Dr. Viral kodierte CxC determinieren den Gewebetropismus von HCMV
WO2005012545A2 (en) * 2003-07-25 2005-02-10 The Regents Of The University Of California Cytomegalovirus gene function and methods for developing antivirals, anti-cmv vaccines, and cmv-based vectors
CA2837748C (en) * 2004-05-25 2016-03-08 Oregon Health And Science University Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
EP1602676A1 (en) 2004-06-01 2005-12-07 SOLVAY (Société Anonyme) Catalytic compositions
WO2006004661A1 (en) * 2004-06-25 2006-01-12 Medimmune Vaccines, Inc. Recombinant human cytomegalovirus and vaccines comprising heterologous antigens
US8668564B2 (en) 2005-01-24 2014-03-11 Solution Champion Limited Jackpot method and system
EP1888622A1 (en) * 2005-05-23 2008-02-20 Oxxon Therapeutics Ltd. Compositions for inducing an immune response against hepatitis b
AU2006284756B2 (en) * 2005-08-31 2012-06-07 Genvec, Inc. Adenoviral vector-based malaria vaccines
EP2614836A3 (en) 2005-10-17 2013-10-23 MedImmune, LLC High growth reassortant influenza A virus
WO2008112146A2 (en) 2007-03-07 2008-09-18 The Trustees Of The University Of Pennsylvania 2d partially parallel imaging with k-space surrounding neighbors based data reconstruction
US20090148447A1 (en) 2007-07-06 2009-06-11 Trubion Pharmaceuticals, Inc. Binding Peptides Having a C-terminally Disposed Specific Binding Domain
SI2215117T2 (en) 2007-10-30 2018-04-30 Genentech, Inc. Purification of the antibody by cation exchange chromatography
WO2010101663A2 (en) 2009-03-06 2010-09-10 Mount Sinai School Of Medicine Of New York University Live attenuated influenza virus vaccines comprising microrna response elements
DK2424571T3 (da) 2009-04-30 2020-05-04 Ospedale San Raffaele Srl Genvektor
EP2516463B1 (en) 2009-12-23 2016-06-15 4-Antibody AG Binding members for human cytomegalovirus
EP2529227B1 (en) 2010-01-27 2015-10-07 Oregon Health & Science University Cytomegalovirus-based immunogenic preparations
WO2011119920A2 (en) * 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
AU2011250191A1 (en) 2010-05-05 2012-11-22 Ulrich Koszinowski Vaccine against beta-herpesvirus infection and use thereof
PT3351636T (pt) 2010-05-14 2020-09-24 Univ Oregon Health & Science Vectores de hcmv e rhcmv recombinantes codificadores de um antigénio heterólogo isolado a partir de um vírus paramyxoviridae e seus usos
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
WO2013040320A1 (en) 2011-09-16 2013-03-21 Oregon Health & Science University Methods and kits used in identifying microrna targets
US20130156808A1 (en) 2011-11-22 2013-06-20 Stipan Jonjic Vaccine comprising beta-herpesvirus
ES2696703T3 (es) 2013-03-05 2019-01-17 Univ Oregon Health & Science Vectores de citomegalovirus que permiten el control del direccionamiento de los linfocitos T
US10428118B2 (en) 2014-07-16 2019-10-01 Oregon Health & Science University Human cytomegalovirus comprising exogenous antigens
EP3048114A1 (en) * 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
AU2016219317A1 (en) 2015-02-10 2017-08-31 Oregon Health & Science University Methods and compositions useful in generating non canonical CD8+ T cell responses
CA3005136A1 (en) 2015-11-20 2017-05-26 Oregon Health & Science University Cmv vectors comprising microrna recognition elements
CA3028827A1 (en) 2016-06-22 2017-12-28 Aeras Recombinant cytomegalovirus vectors as vaccines for tuberculosis
EP3475446A1 (en) 2016-06-27 2019-05-01 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
MA46588A (fr) 2016-10-18 2021-04-14 Univ Oregon Health & Science Vecteurs de cytomégalovirus déclenchant des lymphocytes t limités par des molécules e de complexe majeur d'histocompatibilité

Also Published As

Publication number Publication date
HK1257045A1 (zh) 2019-10-11
US9982241B2 (en) 2018-05-29
LT3351636T (lt) 2020-10-12
AU2022201186A1 (en) 2022-03-17
ES2819623T3 (es) 2021-04-16
EP2569436A2 (en) 2013-03-20
EP3351636A1 (en) 2018-07-25
NO2569436T3 (zh) 2018-04-28
AU2018203259A1 (en) 2018-05-31
CA2798136A1 (en) 2011-11-17
AU2019204982B2 (en) 2021-11-25
LT3333265T (lt) 2020-05-25
DK2569436T3 (en) 2018-03-05
ES2666043T3 (es) 2018-04-30
SI2772265T1 (en) 2018-06-29
SI2569436T1 (en) 2018-05-31
HUE037227T2 (hu) 2018-08-28
HRP20201406T1 (hr) 2021-02-19
RS56958B1 (sr) 2018-05-31
CY1120464T1 (el) 2019-07-10
CY1123362T1 (el) 2021-12-31
ES2660615T3 (es) 2018-03-23
CY1124015T1 (el) 2022-03-24
WO2011143653A3 (en) 2012-05-31
EP3739054A1 (en) 2020-11-18
PT2569436T (pt) 2018-03-05
AU2019204982A1 (en) 2019-08-01
ES2788198T3 (es) 2020-10-20
DK2772265T3 (en) 2018-04-30
HRP20180601T1 (hr) 2018-06-15
EP2772265A3 (en) 2015-01-21
SI3333265T1 (sl) 2020-08-31
DK3333265T3 (da) 2020-04-27
ES2660615T8 (es) 2019-11-04
HRP20200698T1 (hr) 2020-10-02
EP3351636B1 (en) 2020-07-01
AU2018203259A2 (en) 2018-06-07
US9249427B2 (en) 2016-02-02
PT2772265T (pt) 2018-04-20
SI3351636T1 (sl) 2020-11-30
US20190099479A1 (en) 2019-04-04
TR201802741T4 (tr) 2018-03-21
WO2011143650A3 (en) 2016-03-31
EP3333265B1 (en) 2020-02-05
AU2011252792C1 (en) 2016-06-16
PL3351636T3 (pl) 2021-03-08
RS57274B1 (sr) 2018-08-31
US20130136768A1 (en) 2013-05-30
HUE050909T2 (hu) 2021-01-28
WO2011143653A2 (en) 2011-11-17
EP2569436B1 (en) 2017-11-29
HRP20180267T1 (hr) 2018-04-20
CA3040225A1 (en) 2011-11-17
CA2798136C (en) 2019-06-04
PL3333265T3 (pl) 2020-08-10
EP2772265B1 (en) 2018-01-17
AU2011252792B2 (en) 2016-03-03
PL2569436T3 (pl) 2018-05-30
WO2011143650A2 (en) 2011-11-17
LT2772265T (lt) 2018-05-25
EP3333265A1 (en) 2018-06-13
US20160114027A1 (en) 2016-04-28
AU2016201853A1 (en) 2016-06-02
LT2569436T (lt) 2018-03-12
CY1119944T1 (el) 2018-12-12
EP2569436A4 (en) 2013-11-27
PL2772265T3 (pl) 2018-07-31
EP2772265A2 (en) 2014-09-03
HUE049725T2 (hu) 2020-10-28
HUE036122T2 (hu) 2018-06-28
US11266732B2 (en) 2022-03-08
NO2772265T3 (zh) 2018-06-16
PT3351636T (pt) 2020-09-24
EP2569436B8 (en) 2019-10-30

Similar Documents

Publication Publication Date Title
HK1256651A1 (zh) 重組hcmv和rhcmv載體以及它們的用途
HRP20180607T1 (hr) Glikoproteini i rekombinantni vektori cmv
EP2550362A4 (en) CMV GLYCOPROTEINS AND RECOMBINANT VECTORS
HK1208686A1 (zh) 芳香族陽離子肽及其用途
HK1215589A1 (zh) 重組腺病毒及其用途
ZA201301862B (en) Oncolytic adenoviral vectors and methods and uses related thereof
IL222961A0 (en) Novel dna-dinding proteins and uses thereof
EP2646556A4 (en) NEW HYBRID PROMOTER AND RECOMBINANT VECTOR COMPRISING SAME
IL222027A (en) Peptides and their use
EP2721061A4 (en) STABILIZED VARIANT MAML PEPTIDES AND USES THEREOF
EP2566880A4 (en) AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
PL2588491T3 (pl) Nowy peptyd i jego zastosowanie
EP2593595A4 (en) NOVEL PEPTIDES AND USES THEREOF
EP2793921A4 (en) PEPTIDES DERIVED FROM SAPOSIN A AND USES THEREOF
PL2627668T3 (pl) Peptydy i ich zastosowanie
EP2825548A4 (en) MODIFIED KISSPEPTIN PEPTIDES AND USES THEREOF
EP2598636A4 (en) VECTORS AND METHODS FOR EXPRESSION OF RECOMBINANT PROTEINS
EP2610619A4 (en) HEMOCININE-1 RECEPTOR AND HEMOCININE-1-PEPTIDE
EP2553105A4 (en) COMPOSITIONS AND METHOD FOR PRODUCING RECOMBINANT VIRUS VECTORS
EP2598631A4 (en) RECOMBINANT BACTERIUM AND ITS USE
PT3333265T (pt) Vectores de hcmv e rhcmv recombinantes codificadores de um antigénio heterólogo isolado a partir do vírus da hepatite b e seus usos
AU2012902684A0 (en) Recombinant Viral Vectors and Uses Therefor